Literature DB >> 16942126

Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.

Andrew J Palmer, Craig J Currie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16942126     DOI： 10.2165/00019053-200624090-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  9 in total

Review 1.  Guidelines for computer modeling of diabetes and its complications.

Authors: 
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

2.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

Review 3.  A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.

Authors:  Adrian Bagust; Marc Evans; Sophie Beale; Philip D Home; Andrew S Perry; Murray Stewart
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.

Authors:  Arran T Shearer; Adrian Bagust; Andreas Liebl; Oliver Schoeffski; Anita Goertz
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Authors:  Arran T Shearer; Adrian Bagust; F Javier Ampudia-Blasco; Belén Martínez-Lage Alvarez; Isabel Pérez Escolano; Gonzalo París
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

7.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

Authors:  Louis Monnier; Hélène Lapinski; Claude Colette
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

8.  Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

Authors:  H C Gerstein; S Yusuf; R Holman; J Bosch; J Pogue
Journal:  Diabetologia       Date:  2004-08-21       Impact factor: 10.122

9.  A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Authors:  Giancarlo Viberti; Steven E Kahn; Douglas A Greene; William H Herman; Bernard Zinman; Rury R Holman; Steven M Haffner; Daniel Levy; John M Lachin; Rhona A Berry; Mark A Heise; Nigel P Jones; Martin I Freed
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.